Drug-induced urinary retention: Incidence, management and prevention

Drug Safety

Volumn 31, Issue 5, 2008, Pages 373-388

  Verhamme, Katia M C ^a   Sturkenboom, Miriam C J M ^a   Stricker, Bruno H Ch ^a   Bosch, Ruud ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Adrenergic receptor agonists, adverse reactions; Adrenergic receptor antagonists, general; Analgesics, adverse reactions; Antidepressants, adverse reactions; Antiparkinsonians, adverse reactions; Benzodiazepines, adverse reactions

Indexed keywords

AMANTADINE; ANALGESIC AGENT; ANTIPARKINSON AGENT; ARIPIPRAZOLE; ATROPINE; BETHANECHOL; CHLORPHENIRAMINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CITALOPRAM; CLONAZEPAM; DIPHENHYDRAMINE; DISOPYRAMIDE; DISTIGMINE; EBASTINE; FLECAINIDE; FLUOXETINE; FLUVOXAMINE; IPRATROPIUM BROMIDE; NALOXONE; NONSTEROID ANTIINFLAMMATORY AGENT; OXITROPIUM BROMIDE; PROPIVERINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TAMSULOSIN; TIOTROPIUM BROMIDE; TOLTERODINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; ZIPRASIDONE;

ABDOMINAL PAIN; ALLERGIC RHINITIS; ASTHMA; BLADDER CATHETERIZATION; BLURRED VISION; BRADYCARDIA; CHOLINERGIC SYSTEM; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONSTIPATION; DOPAMINERGIC ACTIVITY; DROWSINESS; DRUG ABSORPTION; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HUMAN; INCIDENCE; IRRITABLE COLON; MICTURITION; MYDRIASIS; NAUSEA; OVERACTIVE BLADDER; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW; TREMOR; URINE RETENTION; VOMITING; XEROSTOMIA;

HUMANS; URINARY RETENTION;

EID: 42449098439     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200831050-00002     Document Type: Review

References (125)

1. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Am J Obstet Gynecol 2002 Jul; 187 (1): 116-26
2. Thorpe A, Neal D. Benign prostatic hyperplasia. Lancet 2003 Apr 19; 361 (9366): 1359-67
3. Roehrborn CG. Acute urinary retention: risks and management. Rev Urol 2005; 7 Suppl. 4: S31-41
4. Meigs JB, Barry MJ, Giovannucci E, et al. Incidence rates and risk factors for acute urinary retention: the health professionals followup study. J Urol 1999 Aug; 162 (2): 376-82
5. Jacobsen SJ, Jacobson DJ, Girman CJ, et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol 1997 Aug; 158 (2): 481-7
6. Cathcart P, van der Meulen J, Armitage J, et al. Incidence of primary and recurrent acute urinary retention between 1998 and 2003 in England. J Urol 2006 Jul; 176 (1): 200-4; discussion 4
7. Verhamme KM, Dieleman JP, van Wijk MA, et al. Low incidence of acute urinary retention in the general male population: the triumph project. Eur Urol 2005 Apr; 47 (4): 494-8
8. Temml C, Brossner C, Schatzl G, et al. The natural history of lower urinary tract symptoms over five years. Eur Urol 2003 Apr; 43 (4): 374-80
9. Roehrborn CG. The epidemiology of acute urinary retention in benign prostatic hyperplasia. Rev Urol 2001 Fall; 3 (4): 187-92
10. Klarskov P, Andersen JT, Asmussen CF, et al. Acute urinary retention in women: a prospective study of 18 consecutive cases. Scand J Urol Nephrol 1987; 21 (1): 29-31
11. Glavind K, Bjork J. Incidence and treatment of urinary retention postpartum. Int Urogynecol J Pelvic Floor Dysfunct 2003 Jun; 14 (2): 119-21
12. Teo R, Punter J, Abrams K, et al. Clinically overt postpartum urinary retention after vaginal delivery: a retrospective case-control study. Int Urogynecol J Pelvic Floor Dysfunct 2006 Aug 23; 18 (5): 521-4
13. Turner-Warwick R. Impaired voiding efficiency and retention. Clin Obstet Gynaecol 1978 Apr; 5 (1): 193-207
14. Thomas K, Chow K, Kirby RS. Acute urinary retention: a review of the aetiology and management. Prostate Cancer Prostatic Dis 2004; 7 (1): 32-7
15. Murray K, Massey A, Feneley RC. Acute urinary retention: a urodynamic assessment. Brit J Urol 1984 Oct; 56 (5): 468-73
16. Gatti JM, Perez-Brayfield M, Kirsch AJ, et al. Acute urinary retention in children. J Urol 2001 Mar; 165 (3): 918-21
17. Kurasawa G, Kotani K, Kurasawa M, et al. Causes of chronic retention of urine in the primary care setting. Intern Med (Tokyo, Japan) 2005 Jul; 44 (7): 761-2
18. Ouslander JG. Management of overactive bladder. N Engl J Med 2004 Feb 19; 350 (8): 786-99
19. Kumar V, Templeman L, Chapple CR, et al. Recent developments in the management of detrusor overactivity. Curr Opin Urol 2003 Jul; 13 (4): 285-91
20. Andersson KE, Chapple C, Wein A. The basis for drug treatment of the overactive bladder. World J Urol 2001 Nov; 19 (5): 294-8
21. de Groat WC. Integrative control of the lower urinary tract: preclinical perspective. Brit J Pharmacol 2006 Feb; 147 Suppl. 2: S25-40
22. Andersson KE, Hedlund P. Pharmacologic perspective on the physiology of the lower urinary tract. Urology 2002 Nov; 60 (5 Suppl. 1): 13-20; discussion 1
23. Woodring JH, Martin CA, Keefer B. Esophageal atony and dilatation as a side effect of thiothixene and benztropine. Hosp Community Psychiatry 1993 Jul; 44 (7): 686-8
24. Tueth MJ. Emergencies caused by side effects of psychiatric medications. Am J Emerg Med 1994 Mar; 12 (2): 212-6
25. Gardner DM, Baldessarini RJ, Waraich P. Modern antipsychotic drugs: a critical overview. CMAJ 2005 Jun 21; 172 (13): 1703-11
26. Xomalis D, Bozikas VP, Garyfallos G, et al. Urinary hesitancy and retention caused by ziprasidone. Int Clin Psychopharmacol 2006 Jan; 21 (1): 71-2
27. Bozikas V, Petrikis P, Karavatos A. Urinary retention caused after fluoxetine-risperidone combination. J Psychopharmacol 2001 Jun; 15 (2): 142-3
28. Benazzi F. Urinary retention with fluoxetine-haloperidol combination in a young patient. Can J Psychiatry 1996 Nov; 41 (9): 606-7
29. Benazzi F. Urinary retention with venlafaxine-haloperidol combination [letter]. Pharmacopsychiatry 1997 Jan; 30 (1): 27
30. Benazzi F. Urinary retention with sertraline, haloperidol, and clonazepam combination. Can J Psychiatry 1998 Dec; 43 (10): 1051-2
31. Ulmar G, Schunck H, Kober C. Urinary retention in the course of neuroleptic therapy with haloperidol. Pharmacopsychiatry 1988 Jul; 21 (4): 208-9
32. Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine. Am J Psychiatry 1994 Apr; 151 (4): 619-20
33. Lin CC, Bai YM, Chen JY, et al. A retrospective study of clozapine and urinary incontinence in Chinese in-patients. Acta Psychiatr Scand 1999 Aug; 100 (2): 158-61
34. Fuller MA, Borovicka MC, Jaskiw GE, et al. Clozapine-induced urinary incontinence: incidence and treatment with ephedrine. J Clin Psychiatry 1996 Nov; 57 (11): 514-8
35. Pradhan SC. Clozapine-induced urinary incontinence: facts or artefacts? Acta Psychiatr Scand 2000 May; 101 (5): 410
36. Warner JP, Harvey CA, Barnes TR. Clozapine and urinary incontinence. Int Clin Psychopharmacol 1994 Sep; 9 (3): 207-9
37. Rudorfer MV, Manji HK, Potter WZ. Comparative tolerability profiles of the newer versus older antidepressants. Drug Saf 1994 Jan; 10 (1): 18-46
38. Benazzi F. Urinary retention with reboxetine-fluoxetine combination in a young man. Can J Psychiatry 2000 Dec; 45 (10): 936
39. Lock JD, Gwirtsman HE, Targ EF. Possible adverse drug interactions between fluoxetine and other psychotropics. J Clin Psychopharmacol 1990 Oct; 10 (5): 383-4
40. Gotoh M, Kato K, Saito M, et al. Effects of disopyramide on detrusor muscle contraction: in vitro experiment and report of 3 cases with disopyramide-induced urinary retention. Urol Int 1987; 42 (6): 450-5
41. Ziegelbaum M, Lever H. Acute urinary retention associated with flecainide. Cleve Clin J Med 1990 Jan-Feb; 57 (1): 86-7
42. Rao SS, Hofmann LA, Shakil A. Parkinson's disease: diagnosis and treatment. Am Fam Physician 2006 Dec 15; 74 (12): 2046-54
43. Horstink M, Tolosa E, Bonuccelli U, et al. Review of the therapeutic management of Parkinson's disease: report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES) - Part II, late (complicated) Parkinson's disease. Eur J Neurol 2006 Nov; 13 (11): 1186-202
44. Horstink M, Tolosa E, Bonuccelli U, et al. Review of the therapeutic management of Parkinson's disease: report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section - Part I, early (uncomplicated) Parkinson's disease. Eur J Neurol 2006 Nov; 13 (11): 1170-85
45. Labetoulle M, Frau E, Le Jeunne C. Systemic adverse effects of topical ocular treatments. Presse Med 2005 Apr 23; 34 (8): 589-95
46. Horowitz R, Reynolds S. New oral antihistamines in pediatrics. Pediatr Emerg Care 2004 Feb; 20 (2): 143-6
47. Golightly LK, Greos LS. Second-generation antihistamines: actions and efficacy in the management of allergic disorders. Drugs 2005; 65 (3): 341-84
48. 1-antihistamines. N Engl J Med 2004 Nov 18; 351 (21): 2203-17
49. Lin AY, Zahtz G, Myssiorek D. Astemizole-associated urinary retention. Otolaryngol Head Neck Surg 1991 Jun; 104 (6): 893-4
50. McGann KP, Pribanich S, Graham JA, et al. Diphenhydramine toxicity in a child with varicella: a case report. J Fam Pract 1992 Aug; 35 (2): 210, 3-4
51. Appleton S, Jones T, Poole P, et al. Ipratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006; (3): CD006101
52. Gross NJ. Anticholinergic agents in asthma and COPD. Eur J Pharmacol 2006 Mar 8; 533 (1-3): 36-9
53. Pras E, Stienlauf S, Pinkhas J, et al. Urinary retention associated with ipratropium bromide. DICP 1991 Sep; 25 (9): 939-40
54. Lozewicz S. Bladder outflow obstruction induced by ipratropium bromide. Postgrad Med J 1989 Apr; 65 (762): 260-1
55. Barr RG, Bourbeau J, Camargo CA, et al. Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. Thorax 2006 Oct; 61 (10): 854-62
56. Tashkin DP. Is a long-acting inhaled bronchodilator the first agent to use in stable chronic obstructive pulmonary disease? Curr Opin Pulm Med 2005 Mar; 11 (2): 121-8
57. Novara G, Galfano A, Ficarra V, et al. Anticholinergic drugs in patients with bladder outlet obstruction and lower urinary tract symptoms: a systematic review. Eur Urol 2006 Oct; 50 (4): 675-83
58. Kaplan SA, Roehrborn CG, Rovner ES, et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 2006 Nov 15; 296 (19): 2319-28
59. Padala PR, Sadiq HJ, Padala KP. Urinary obstruction with citalopram and aripiprazole combination in an elderly patient. J Clin Psychopharmacol 2006 Dec; 26 (6): 667-8
60. Thor KB. Serotonin and norepinephrine involvement in efferent pathways to the urethral rhabdosphincter: implications for treating stress urinary incontinence. Urology 2003 Oct; 62 (4 Suppl. 1): 3-9
61. Kasper S. Managing reboxetine-associated urinary hesitancy in a patient with major depressive disorder: a case study. Psychopharmacology (Berl) 2002 Feb; 159 (4): 445-6
62. Kasper S, Wolf R. Successful treatment of reboxetine-induced urinary hesitancy with tamsulosin. Eur Neuropsychopharmacol 2002 Apr; 12 (2): 119-22
63. Garnier R, Azoyan P, Chataigner D, et al. Acute fluvoxamine poisoning. J Int Med Res 1993 Jul-Aug; 21 (4): 197-208
64. Hansen LK. Venlafaxine-induced increase in urinary frequency in 3 women. J Clin Psychiatry 2004 Jun; 65 (6): 877-8.
65. Moghaddas F, Lidfeldt J, Nerbrand C, et al. Prevalence of urinary incontinence in relation to self-reported depression, intake of serotonergic antidepressants, and hormone therapy in middle-aged women: a report from the Women's Health in the Lund Area study. Menopause 2005 May-Jun; 12 (3): 318-24
66. Shearer WT, Schreiner RL, Marshall RE. Urinary retention in a neonate secondary to maternal ingestion of nortriptyline. J Pediatr 1972 Sep; 81 (3): 570-2
67. Remick RA. Anticholinergic side effects of tricyclic antidepressants and their management. Prog Neuropsychopharmacol Biol Psychiatry 1988; 12 (2-3): 225-31
68. De Lima MS, Hotopf M. Benefits and risks of pharmacotherapy for dysthymia: a systematic appraisal of the evidence. Drug Saf 2003; 26 (1): 55-64
69. Parker J, Lahmeyer H. Maprotiline poisoning: a case of cardiotoxicity and myoclonic seizures. J Clin Psychiatry 1984 Jul; 45 (7): 312-4
70. Caksen H, Odabas D. Urinary retention due to clonazepam in a child with dyskinetic cerebral palsy. J Emerg Med 2004 Feb; 26 (2): 244
71. Maany I, Greenfield H, Dhopesh V, et al. Urinary retention as a possible complication of long-term diazepam abuse [letter]. Am J Psychiatry 1991 May; 148 (5): 685
72. Burger DH, Kappetein AP, Boutkan H, et al. Prevention of urinary retention after general surgery: a controlled trial of carbachol/diazepam versus alfusozine. J Am Coll Surg 1997 Sep; 185 (3): 234-6
73. O'Reilly PH. Postoperative urinary retention in men. BMJ (Clin Res Ed) 1991 Apr 13; 302 (6781): 864
74. Meyboom RH, Brodie-Meijer CC, Diemont WL, et al. Bladder dysfunction during the use of tramadol. Pharmacoepidemiol Drug Saf 1999 Apr; 8 Suppl. 1: S63-4
75. Malinovsky JM, Le Normand L, Lepage JY, et al. The urodynamic effects of intravenous opioids and ketoprofen in humans. Anesth Analg 1998 Aug; 87 (2): 456-61
76. Koch CA, Grinberg GG, Farley DR. Incidence and risk factors for urinary retention after endoscopic hernia repair. Am J Surg 2006 Mar; 191 (3): 381-5
77. Dolin SJ, Cashman JN. Tolerability of acute postoperative pain management: nausea, vomiting, sedation, pruritus, and urinary retention: evidence from published data. Br J Anaesth 2005 Nov; 95 (5): 584-91
78. Murray K. Acute urinary retention associated with sublingual buprenorphine. BMJ (Clin Res Ed) 1983 Mar 5; 286 (6367): 763-4
79. Chen Y-P, Chen S-R, Pan H-L. Systemic morphine inhibits dorsal horn projection neurons through spinal cholinergic system independent of descending pathways. J Pharmacol Exp Ther 2005; 314 (2): 611-7
80. Sakakibara R, Uchiyama T, Asahina M, et al. Amezinium metilsulfate, a sympathomimetic agent, may increase the risk of urinary retention in multiple system atrophy. Clin Auton Res 2003 Feb; 13 (1): 51-3
81. Napolez A, Lauth W. Drug-induced acute urinary retention. Ann Emerg Med 1988 Dec; 17 (12): 1367
82. Glidden RS, DiBona FJ. Urinary retention associated with ephedrine. J Pediatr 1977 Jun; 90 (6): 1013-4
83. Taylor III JA, Kuchel GA. Detrusor underactivity: clinical features and pathogenesis of an underdiagnosed geriatric condition. J Am Geriatr Soc 2006 Dec; 54 (12): 1920-32
84. Inman DS, Greene D. The agony and the ecstasy: acute urinary retention after MDMA abuse. BJU Int 2003 Jan; 91 (1): 123
85. Bryden AA, Rothwell PJ, O'Reilly PH. Urinary retention with misuse of "ecstasy". BMJ 1995 Feb 25; 310 (6978): 504
86. Park JM, Houck CS, Sethna NF, et al. Ketorolac suppresses postoperative bladder spasms after pediatric ureteral reimplantation. Anesth Analg 2000 Jul; 91 (1): 11-5
87. Gruenenfelder J, McGuire EJ, Faerber GJ. Acute urinary retention associated with the use of cyclooxygenase-2 inhibitors [letter]. J Urol 2002 Sep; 168 (3): 1106
88. Verhamme KM, Dieleman JP, Van Wijk MA, et al. Nonsteroidal anti-inflammatory drugs and increased risk of acute urinary retention. Arch Intern Med 2005 Jul 11; 165 (13): 1547-51
89. Hashim H, Abrams P. Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations. Drugs 2004; 64 (15): 1643-56
90. Owens RG, Karram MM. Comparative tolerability of drug therapies used to treat incontinence and enuresis. Drug Saf 1998 Aug; 19 (2): 123-39
91. Haeusler G, Leitich H, van Trotsenburg M, et al. Drug therapy of urinary urge incontinence: a systematic review. Obstet Gynecol 2002 Nov; 100 (5 Pt 1): 1003-16
92. Khurana V, Nehme O, Khurana R, et al. Urinary retention secondary to detrusor muscle hypofunction after botulinum toxin injection for achalasia. Am J Gastroenterol 2001 Nov; 96 (11): 3211-2
93. Eicher JC, Chalopin JM, Tanter Y, et al. Nicardipine and urinary retention [letter]. JAMA 1987 Dec 18; 258 (23): 3388
94. Winge K, Werdelin LM, Nielsen KK, et al. Effects of dopaminergic treatment on bladder function in Parkinson's disease. Neurourol Urodyn 2004; 23 (7): 689-96
95. Jotkowitz S. Urinary retention as complication of levodopa therapy [letter]. JAMA 1976 Jun 14; 235 (24): 2586
96. Tfayli A, Hentschel P, Madajewicz S, et al. Toxicities related to intraarterial infusion of cisplatin and etoposide in patients with brain tumors. J Neurooncol 1999 Mar; 42 (1): 73-7
97. Taieb S, Trillet-Lenoir V, Rambaud L, et al. Lhermitte sign and urinary retention: atypical presentation of oxaliplatin neurotoxicity in four patients. Cancer 2002 May 1; 94 (9): 2434-40
98. Bay A, Oner AF, Etlik O, et al. Myelopathy due to intrathecal chemotherapy: report of six cases. J Pediatr Hematol Oncol 2005 May; 27 (5): 270-2
99. McQuillan O, Higgins SP. Acute urinary retention following self treatment of genital warts with imiquimod 5% cream. Sex Transm Infect 2004 Oct; 80 (5): 419-20
100. Friedman AJ. Acute urinary retention after gonadotropin-releasing hormone agonist treatment for leiomyomata uteri. Fertil Steril 1993 Mar; 59 (3): 677-8
101. Charalabopoulos K, Papalimneou V, Charalabopoulos A, et al. Two new adverse effects of isotretinoin [letter]. Br J Dermatol 2003 Mar; 148 (3): 593
102. Meythaler JM, Guin-Renfroe S, Brunner RC, et al. Intrathecal baclofen for spastic hypertonia from stroke. Stroke 2001 Sep; 32 (9): 2099-109
103. de Moor RA, Diemont WL, Visser MO, et al. Urinary retention in 2 children after the use of antiemetic agents during acute gastroenteritis [in Dutch]. Ned Tijdschr Geneeskd 2005 Jun 25; 149 (26): 1472-4
104. Kohli-Kumar M, Pearson AD, Sharkey I, et al. Urinary retention: an unusual dystonic reaction to continuous metoclopramide infusion. DICP 1991 May; 25 (5): 469-70
105. Steiner I, Birmanns B. Carbamazepine-induced urinary retention in long-standing diabetes mellitus. Neurology 1993 Sep; 43 (9): 1855-6
106. Saborio DV, Kennedy II WA, Hoke GP. Acute urinary retention secondary to urethral inflammation from a vaginal contraceptive suppository in a 17-year-old boy. Urol Int 1997; 58 (2): 128-30
107. Chua KS, Kong KH. An unusual case of Dantrolene sodium-induced urinary retention in post-traumatic minimally responsive state. Brain Inj 2005 Nov; 19 (12): 1063-6
108. Owens GR, Tannenbaum R. Theophylline-induced urinary retention. Ann Intern Med 1981 Feb; 94 (2): 212-3
109. Hassan SN. Urinary retention with theophylline [letter]. South Med J 1983 Mar; 76 (3): 408
110. Tyson LB, Gralla RJ, Clark RA, et al. Phase 1 trial of levonantradol in chemotherapy-induced emesis. Am J Clin Oncol 1985 Dec; 8 (6): 528-32
111. McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003 Dec 18; 349 (25): 2387-98
112. Hameed A, Charles TJ. Cholinergic crisis following treatment of postoperative urinary retention with distigmine bromide. Br J Clin Pract 1994 Mar-Apr; 48 (2): 103-4
113. Barendrecht MM, Oelke M, Laguna MP, et al. Is the use of parasympathomimetics for treating an underactive urinary bladder evidence-based? BJU Int 2007 Apr; 99 (4): 749-52
114. Rawal N, Mollefors K, Axelsson K, et al. Naloxone reversal of urinary retention after epidural morphine [letter]. Lancet 1981 Dec 19-26; 2 (8260-61): 1411
115. Wang J, Pennefather S, Russell G. Low-dose naloxone in the treatment of urinary retention during extradural fentanyl causes excessive reversal of analgesia. Br J Anaesth 1998 Apr; 80 (4): 565-6
116. Malinovsky JM, Lepage JY, Karam G, et al. Nalbuphine reverses urinary effects of epidural morphine: a case report. J Clin Anesthes 2002 Nov; 14 (7): 535-8
117. Walder B, Schafer M, Henzi I, et al. Efficacy and safety of patient-controlled opioid analgesia for acute postoperative pain: a quantitative systematic review. Acta Anaesthesiol Scand 2001 Aug; 45 (7): 795-804
118. Kehlet H, Dahl JB. The value of "multimodal" or "balanced analgesia" in postoperative pain treatment. Anesth Analg 1993 Nov; 77 (5): 1048-56
119. Remy C, Marret E, Bonnet F. Effects of acetaminophen on morphine side-effects and consumption after major surgery: meta-analysis of randomized controlled trials. Br J Anaesth 2005 Apr; 94 (4): 505-13
120. Turan A, Karamanlioglu B, Memis D, et al. Analgesic effects of gabapentin after spinal surgery. Anesthesiology 2004 Apr; 100 (4): 935-8
121. Marret E, Kurdi O, Zufferey P, et al. Effects of nonsteroidal antiinflammatory drugs on patient-controlled analgesia morphine side effects: meta-analysis of randomized controlled trials. Anesthesiology 2005 Jun; 102 (6): 1249-60
122. Romsing J, Moiniche S, Mathiesen O, et al. Reduction of opioid-related adverse events using opioid-sparing analgesia with COX-2 inhibitors lacks documentation: a systematic review. Acta Anaesthesiol Scand 2005 Feb; 49 (2): 133-42
123. Gottesman L, Milsom JW, Mazier WP. The use of anxiolytic and parasympathomimetic agents in the treatment of post-operative urinary retention following anorectal surgery: a prospective, randomized, double-blind study. Dis Colon Rectum 1989 Oct; 32 (10): 867-70
124. Hershberger JM, Milad MP. A randomized clinical trial of lorazepam for the reduction of postoperative urinary retention. Obstet Gynecol 2003 Aug; 102 (2): 311-6
125. Szabadi E. Doxazosin for reboxetine-induced urinary hesitancy. Br J Psychiatry 1998 Nov; 173: 441-2